Signator, John Hancock's IBD, taps new CEO

Signator, John Hancock's IBD, taps new CEO
NOV 02, 2016
Culminating a busy year, Signator Investors Inc., John Hancock's independent broker-dealer, said on Thursday it was appointing a new CEO to replace its longtime chief, Brian Heapps, who is retiring. Signator has tapped industry and firm veteran Christopher Maryanopolis, currently the firm's president, to replace Mr. Heapps. The change takes effect at the start of next year, the company said in a press release. It has been an active 12 months for Signator, which had 1,440 affiliated producing reps at the end of 2015, according to InvestmentNews data. Signator spent the past year increasing that tally. Last November, John Hancock said it was acquiring up to 1,100 advisers from Transamerica Financial Advisors Inc., or about one-quarter of those affiliated with Transamerica at the time. After excluding close to 200 of those advisers, Signator in May closed on the deal and acquired 883 registered reps and advisers from Transamerica. Those advisers had $25 billion in client assets and Signator now has close to $50 billion in assets under management and close to 2,200 advisers under its roof. For the past 10 years, Mr. Heapps was instrumental in changing Signator from a company in which its advisers sold proprietary products to a firm with an open architecture model, according to the company. Mr. Maryanopolis was originally brought in to Signator in 2007 to oversee the operations, service and trading areas of the firm, the company said in its press release. He quickly moved on to become head of the broker-dealer and corporate registered investment adviser. “Although Signator has changed dramatically in the past 10 years, I believe the next 10 could be equally as transformative,” said Mr. Heapps in the company statement. Mr. Maryanopolis “has a great understanding of all the facets of our business as well as what is needed to succeed in today's ever-changing regulatory, advisor and customer environments.”

Latest News

GLP-1 users are trading retirement savings for their prescriptions
GLP-1 users are trading retirement savings for their prescriptions

A Nationwide survey finds 47% of GLP-1 users have never discussed the drugs’ financial impact with an advisor, even as many dip into savings.

Inspired Healthcare sale price of properties is 59% of $1.2 billion sold by advisors
Inspired Healthcare sale price of properties is 59% of $1.2 billion sold by advisors

The hundreds of millions of dollars from a sale of Inspired Healthcare properties does not mean an immediate windfall for investors.

Class action alleges Webull misled investors about China operations
Class action alleges Webull misled investors about China operations

Its SEC filings said one thing - a congressional probe said another.

Investors accuse Netcapital of inflating revenue through sham deals
Investors accuse Netcapital of inflating revenue through sham deals

Sham agreements allegedly padded revenue by 345%.

Pre-retirees are looking for flexibility, security, and guidance when it comes to retirement income: Cerulli
Pre-retirees are looking for flexibility, security, and guidance when it comes to retirement income: Cerulli

"Most pre-retirees are uncomfortable making key retirement income decisions without an advisor's help," said Chris Bailey of Cerulli.

SPONSORED Built on insurance experience to deliver on long-term promises

Knighthead Life entered the market with a competitive MYGA. A strong launch earned advisor confidence and paved the way for FIAs.

SPONSORED In the Age of AI, Trust Becomes the Advisor's Greatest Asset

As AI makes financial information more accessible than ever, Lana Hock explains why human judgment, trust, and empathy remain the qualities clients value most in a financial advisor